Cancer Immunology Research · 2018 · 108 citations · 37 references
Life SciencesCell BiologyImmunologyImmunotherapyInnate ImmunitySignal TransductionImmune Cell SignalingNatural Killer Cell BiologyNatural Killer Cell FunctionNatural Killer Cell RegulationNatural Killer Cell TherapyReceptor-mediated TargetingCar Natural Killer Cell TherapyCar-nk Cell TherapyChimeric Antigen Receptor Natural Killer CellsFunctional PotentialHla Class I MoleculesKiller-cell Immunoglobulin-like ReceptorsNatural Killer Cell EngineeringPrimary Cells
Abstract Natural killer (NK) cells hold potential as a source of allogeneic cytotoxic effector cells for chimeric antigen receptor (CAR)-mediated therapies. Here, we explored the feasibility of transfecting CAR-encoding mRNA into primary NK cells and investigated how the intrinsic potential of discrete NK-cell subsets affects retargeting efficiency. After screening five second- and third-generation anti-CD19 CAR constructs with different signaling domains and spacer regions, a third-generation CAR with the CH2-domain removed was selected based on its expression and functional profiles. Kinetics experiments revealed that CAR expression was optimal after 3 days of IL15 stimulation prior to transfection, consistently achieving over 80% expression. CAR-engineered NK cells acquired increased degranulation toward CD19+ targets, and maintained their intrinsic degranulation response toward CD19− K562 cells. The response of redirected NK-cell subsets against CD19+ targets was dependent on their intrinsic thresholds for activation determined through both differentiation and education by killer cell immunoglobulin-like receptors (KIR) and/or CD94/NKG2A binding to self HLA class I and HLA-E, respectively. Redirected primary NK cells were insensitive to inhibition through NKG2A/HLA-E interactions but remained sensitive to inhibition through KIR depending on the amount of HLA class I expressed on target cells. Adaptive NK cells, expressing NKG2C, CD57, and self-HLA–specific KIR(s), displayed superior ability to kill CD19+, HLA low, or mismatched tumor cells. These findings support the feasibility of primary allogeneic NK cells for CAR engineering and highlight a need to consider NK-cell diversity when optimizing efficacy of cancer immunotherapies based on CAR-expressing NK cells. Cancer Immunol Res; 6(4); 467–80. ©2018 AACR.
37
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp, Michael Kalos, David M. Barrett et al. · New England Journal of Medicine · 2013 · 3.5K citations · Full text
Michael C. Milone, Jonathan D. Fish, Carmine Carpenito et al. · Molecular Therapy · 2009 · 1.2K citations · Full text
Life Sciences, Immunology, Oncology +17